Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Test delivers results in just 18 minutes, enabling faster laboratory workflows and patient management during outbreaks
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment
These findings follow positive Phase 3 results presented earlier this year
Merck will showcase results in innovative solutions in HIV treatment and prevention
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
